Great Basin Initiates Clinical Trial For Bordatella Direct Test
17 May 2016 - 1:00PM
Business Wire
First of five clinical trial starts the Company
expects in 2016
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular
diagnostics company, today announced it has initiated a clinical
trial for its sample-to-result Bordatella Direct Test, which will
detect, directly from patient specimen, Bordatella pertussis, a
bacterium causing a highly contagious respiratory disease commonly
known as whooping cough. This is the first of five clinical trials
the Company plans to initiate in 2016.
“As we’ve committed to our customers and stockholders, 2016 is
going to be a time of continued R&D progress and customer
growth for Great Basin,” said Ryan Ashton, co-founder and Chief
Executive Officer of Great Basin Scientific. “The on-time start of
the clinical trial for our Bordatella Direct Test is indicative of
our commitment to delivering on our menu targets and represents
Great Basin’s dedication to meeting strategic objectives.”
Great Basin intends to submit its 510(K) Clearance application
for the Bordatella Direct Test to the U.S. Food & Drug
Administration (FDA) in the fourth quarter of this year, on-track
with guidance previously issued by the Company.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that
commercializes breakthrough chip-based technologies. The Company is
dedicated to the development of simple, yet powerful,
sample-to-result technology and products that provide fast,
multiple-pathogen diagnoses of infectious diseases. The Company’s
vision is to make molecular diagnostic testing so simple and
cost-effective that every patient will be tested for every serious
infection, reducing misdiagnoses and significantly limiting the
spread of infectious disease. More information can be found on the
company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statements regarding
the Company’s continuing business efforts related to its products,
including but not limited to planned tests to be brought to
clinical trial in 2016. Forward-looking statements involve risk and
uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risk and uncertainties
include, but are not limited to: (i) our limited operating history
and history of losses; (ii) our ability to develop and
commercialize new products and the timing of commercialization;
(iii) our ability to obtain capital when needed; and (iv) other
risks set forth in the Company’s filings with the Securities and
Exchange Commission, including the risks set forth in the company’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2015. These forward-looking statements speak only as of the date
hereof and Great Basin Scientific specifically disclaims any
obligation to update these forward-looking statements, except as
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160517005654/en/
Media:ICRKate Ottavio Kent,
203.682.8276Kate.Ottavio-Kent@icrinc.comorInvestor
Relations:CorProminenceScott Gordon,
516.222.2560gbinfo@corprominence.comorICRDavid Clair,
646.277.1266David.Clair@icrinc.com